These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10553808)

  • 1. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
    Purvis K; Egdetveit I; Christiansen E
    Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
    Kunelius P; Lukkarinen O
    Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
    Sexton WJ; Benedict JF; Jarow JP
    J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
    Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
    Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
    Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
    Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction.
    Soderdahl DW; Thrasher JB; Hansberry KL
    Br J Urol; 1997 Jun; 79(6):952-7. PubMed ID: 9202565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic.
    Armstrong DK; Convery A; Dinsmore WW
    Int J STD AIDS; 1993; 4(4):214-6. PubMed ID: 8399501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment.
    Brock G; Tu LM; Linet OI
    Urology; 2001 Mar; 57(3):536-41. PubMed ID: 11248634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient satisfaction with pharmacologic erection program.
    Hollander JB; Gonzalez J; Norman T
    Urology; 1992 May; 39(5):439-41. PubMed ID: 1580034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
    Kiely EA; Bloom SR; Williams G
    Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic roles of intracavernosal papaverine.
    Goldstein I; Payton T; Padma-Nathan H
    Cardiovasc Intervent Radiol; 1988 Aug; 11(4):237-9. PubMed ID: 3147138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study.
    Porst H; Buvat J; Meuleman E; Michal V; Wagner G
    Int J Impot Res; 1998 Dec; 10(4):225-31. PubMed ID: 9884918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
    Chao R; Clowers DE
    Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.